LB Pharmaceuticals Stock
LB Pharmaceuticals Inc Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Heather D. Turner
- Employees
- 49
- Market cap
- $1.2 B
- IPO
- 11/09/2025
- Web
- lbpharma.us
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of…
LB Pharmaceuticals stock: price history
1D
+0.1%
1W
-1.3%
1M
-13.7%
6M
+20.4%
YTD
+65.0%
1Y
+124.0%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~1% weaker price swings than usual
LB Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 16/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
LB Pharmaceuticals Inc is in the clinical development stage and focuses on developing innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. A key component of the portfolio is the investigational drug LB-102, a methylated variant of amisulpride. As the company is still in the research phase, it currently generates no revenue from product sales.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about LB Pharmaceuticals
Analyst assessment of LB Pharmaceuticals
PRICE TARGET LOW
US$35.00
CONSENSUS
US$59.78
MEDIAN
US$60.00
PRICE TARGET HIGH
US$80.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 05/10/2026
LB Pharmaceuticals stock metrics
P/E
-12.37
P/B
3.33
EV/EBITDA
-10.35
RETURN ON EQUITY
-15.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
74.2%
FLOAT SHARES
23,922,791
AVG. DAILY VOLUME (30D)
405,718
Institutional holders
Comparable stocks
Frequently asked questions about LB Pharmaceuticals stock
What does LB Pharmaceuticals do?
LB Pharmaceuticals Inc Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Heather D. Turner, the company employs around 49 people.
The IPO was on 11/09/2025; the stock trades on NASDAQ under the ticker LBRX.
What do analysts say about LB Pharmaceuticals stock?
4 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$59.78, ranging from US$35.00 to US$80.00, with a median of US$60.00.
This is an external assessment, not a statement by Market Jury.
When does LB Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -1% stronger than usual.
Does LB Pharmaceuticals pay a dividend?
No, LB Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to LB Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get LB Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess LB Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.